Alzheimers

New State Legislation Mandates Insurance Coverage for Alzheimer’s Biomarker Tests, Paving the Way for Early Detection

by

In Nashville, Tennessee, a pivotal shift in healthcare policy has emerged as new laws mandate insurance companies to cover biomarker testing for Alzheimer’s disease. This change marks a significant advancement in the efforts to diagnose and manage a condition affecting millions of Americans. The legislation, recently passed, aims to empower individuals and families affected by Alzheimer’s by improving access to diagnostic tools essential for early detection. Experts advocate that biomarker tests can provide crucial insights into the disease, enabling healthcare providers to tailor treatments more effectively. Biomarker testing involves analyzing biological samples to identify specific … Read more

Massachusetts Legislators Gather at Anna Maria College to Advocate for Alzheimer’s and Dementia Care

by

Paxton, Massachusetts – On February 15, Anna Maria College and the Molly Bish Center hosted their 3rd Annual Legislative Breakfast, focusing on the protection of vulnerable populations such as children and the elderly. The event brought together senators and representatives from Massachusetts to express their support for proposed legislation regarding Alzheimer’s Disease and Dementia. The legislators in attendance included Representative David LeBoeuf, Representative Meghan Kilcoyne, Representative James J. O’Day, Representative Danielle Gregoire, as well as representatives from the staff of representative David Muradian, Jr. and senator Ryan Fattman. During the Legislative Breakfast, the proposed legislation … Read more

Pharmaceutical Company PDL BioPharma Files Lawsuit Against Eli Lilly and Company Over Alzheimer’s Treatment Compensation

by

INDIANAPOLIS, IN — Nevada-based company PDL BioPharma, Inc. has filed a lawsuit against Eli Lilly and Company in the U.S. District Court for the Southern District of Indiana. PDL alleges that Eli Lilly used its technology to develop an Alzheimer’s disease treatment without compensating PDL. According to the lawsuit filed on December 21, 2023, PDL claims that Eli Lilly used its antibody humanization technology to create donanemab, a treatment for Alzheimer’s. Donanemab is expected to receive FDA approval in the first quarter of 2024. The lawsuit refers to a 2000 agreement between Eli Lilly and … Read more